Crescendo Biologics Ltd
About Crescendo Biologics
Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.
Crescendo’s technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The Company has raised £4.5 million in seed funding from leading life sciences investors, Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.
- Industry : Biotechnology
News about Crescendo Biologics
11-Jan-2022 | business & finance
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech
02-May-2018 | business & finance
Crescendo Biologics Ltd. Raises $70 Million in Series B Financing
Crescendo Biologics Ltd announced that it has completed a $70 million (€57 million) Series B financing. The funds will be used to advance the development ...
18-Apr-2018 | science
Crescendo Biologics first major milestone in collaboration with Takeda reached
Crescendo Biologics Ltd, the developer of multifunctional biologics, including targeted T-cell engagers, announced that it has achieved the first major ...
16-Jun-2017 | people
Crescendo Biologics appoints new Chief Business Officer
Crescendo Biologics Ltd (Crescendo) announced that Edward J. “Tad” Stewart has joined the company as Chief Business Officer. Dr. Peter Pack, CEO of ...
29-May-2015 | research and development
Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award
Crescendo Biologics Limited announces it is expanding its antibody drug conjugate (ADC) programme with the support of a Biomedical Catalyst Award from the ...
22-Jan-2013 | research and development
Crescendo announces the Crescendo Mouse
Technology generates superior human single domain antibody VH fragments in a transgenic mouse
24-Jun-2011 | people
Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
Crescendo Biologics Limited announced the appointment of Matthew Roe as Chief Business Officer. Matthew joins Crescendo from Genzyme Corporation where he ...